SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-062975
Filing Date
2023-11-13
Accepted
2023-11-13 16:16:04
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acor-20231113.htm   iXBRL 8-K 45917
2 EX-99.1 acor-ex99_1.htm EX-99.1 354945
3 GRAPHIC img123754176_0.jpg GRAPHIC 6064
  Complete submission text file 0000950170-23-062975.txt   542116

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acor-20231113_lab.xml EX-101.LAB 13360
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acor-20231113_pre.xml EX-101.PRE 9839
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acor-20231113.xsd EX-101.SCH 2463
8 EXTRACTED XBRL INSTANCE DOCUMENT acor-20231113_htm.xml XML 4711
Mailing Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965
Business Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965 914-347-4300
Acorda Therapeutics, Inc. (Filer) CIK: 0001008848 (see all company filings)

IRS No.: 133831168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31938 | Film No.: 231398975
SIC: 2836 Biological Products, (No Diagnostic Substances)